Sign In
Buy CGEN
$2.19
-0.0700 (-3.10%)
At Close: Jun 03, 2026
Why Compugen Stock Is Rising Again Today
11:41am, Thursday, 29'th Jul 2021
Momentum is carrying over from the company's second-quarter update on Wednesday.
Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call Transcript
03:10pm, Wednesday, 28'th Jul 2021
Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call Transcript
Why Compugen Stock Is Jumping Today
12:12pm, Wednesday, 28'th Jul 2021
Investors were especially interested in the company's pipeline update.
HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
07:00am, Thursday, 15'th Jul 2021
HOLON, Israel , July 15, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery today announced that the first pat
Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
07:00am, Wednesday, 14'th Jul 2021
HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study
07:00am, Wednesday, 30'th Jun 2021
HOLON, Israel, June 30, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first pa
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
07:00am, Tuesday, 29'th Jun 2021
HOLON, Israel, June 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation
Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients
08:02am, Tuesday, 08'th Jun 2021
Compugen Ltd (NASDAQ: CGEN) has announced updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and in a dose-escalation combination study with Bristol-Myers
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
07:00am, Tuesday, 08'th Jun 2021
HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phas
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
07:00am, Tuesday, 01'st Jun 2021
HOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of it
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2021 Results - Earnings Call Transcript
02:34pm, Thursday, 13'th May 2021
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2021 Results - Earnings Call Transcript
Why Compugen Stock Is Jumping Today
11:40am, Thursday, 13'th May 2021
Investors liked what the company had to say in its Q1 update.
Compugen Reports First Quarter 2021 Results
07:00am, Thursday, 13'th May 2021
HOLON, Israel, May 13, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results
Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar Series
07:00am, Tuesday, 11'th May 2021
HOLON, Israel, May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph
